Patent details

Basic Information

Publication number:

EP3158991

PCT Application Number:

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP160203634

PCT Publication Number:

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

FORMULATIONS OF BENDAMUSTINE

French Title of Invention:

FORMULATIONS DE BENDAMUSTINE

German Title of Invention:

FORMULIERUNGEN AUS BENDAMUSTIN

SPC Number:

Dates

Filing date:

28/01/2011

Grant date:

17/03/2021

EP Publication Date:

26/04/2017

PCT Publication Date:

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

17/03/2021

EP B1 Publication Date:

17/03/2021

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

28/01/2022

Expiration date:

28/01/2031

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

10/03/2021

 

 

Name:

Eagle Pharmaceuticals, Inc.

Address:

50 Tice Boulevard, Woodcliff Lake, NJ 07677, United States (US)

Inventor

1

Name:

Palepu, Nagesh R.

Address:

United States (US)

2

Name:

Buxton, Philip Christopher

Address:

United Kingdom (GB)

Priority

Priority Number:

299100 P

Priority Date:

28/01/2010

Priority Country:

United States (US)

Classification

IPC classification:

A61K 9/08; A61K 31/4184; A61K 47/20; A61P 35/00; A61K 47/10;

Publication

European Patent Bulletin

1

Issue number:

202111

Publication date:

17/03/2021

Description:

Grant (B1)

2

Issue number:

202116

Publication date:

21/04/2021

Description:

Application number/publication number of the divisional application (Art. 76) changed

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages